Insomnia Market Research Report - Forecast to 2030

Insomnia Market Research Report, by types of therapy (Pharmacological therapy and Non Pharmacological therapy), by drug formulation (Capsules, Tablet and others), by type of diseases (poor quality of sleep, sleep maintenance and other) - Forecast till 2030

ID: MRFR/Pharma/0102-HCR | December 2022 | Region: Global | 85 Pages         

Insomnia Market

Insomnia Market to register a CAGR of 3.11% and reach a value of USD 6.6 Billion by 2030.


By types of therapy Pharmacological therapy Non Pharmacological therapy
By drug formulation Capsules Tablet others
By type of diseases poor quality of sleep sleep maintenance and other

Key Players

  • Vanda Pharmaceuticals Inc. (US)
  • Neurim (Switzerland)
  • Eisai
  • Purdue Pharma L.P. (US)
  • Merck & Co Inc (US)
  • Pfizer
  • Astellas (UK)
  • Flynn Pharma (UK)
  • Takeda Pharmaceutical Company (Japan)
  • SkyePharma (UK)
  • Meda Consumer Healthcare Inc (US)
  • Sanofi (France)
  • Biocodex S A (France)
  • Pernix Therapeutics (US)
  • Consumer Healthcare Inc. (Canada)
  • Purdue Pharma L.P. (US)
  • Dainippon Sumitomo (Japan)


  • Increased stress and panic
  • rising incidence of insomnia
Speak to Analyst Request a Free Sample

Insomnia Market Overview

The insomnia market is expected to attain a 3.11% CAGR to reach USD 6.6 billion from 2022-2030 owing to rate at which insomnia is being diagnosed and the demand for treatments of different kinds. Insomnia is commonly recognized and understood as a common sleep disorder common amongst people of different age groups. Also, difficulty in sleeping is often categorized as a person having insomnia. This can exist in an independent state and also, can be conjugated with other kinds of psychiatric issues. It is a lesser-known fact that insomnia is more common with females and the condition is likely to increase during life phases like pregnancy and postpartum, along with the menopause cycle. However, the exact cause of insomnia is still an unknown mystery that is yet to be discovered. There have been many types of research that show that there is an important role of the biological, psychological, alongside behavioral aspects that result at the beginning of insomnia in various individuals. There are both pharmacological, along with the non-pharmacological treatment available in the insomnia market for helping patients that suffer from insomnia. 

COVID 19 Analysis

The arrival of the coronavirus pandemic has caused both physical and mental harm. There is no doubt in saying that the fatal virus has taken many lives and curbed the normalcy and pace at which the markets used to function before the pandemic. Also, the lockdown imposed by the government and the slow rate of the market functions has left people jobless. The concern for growth, earnings, and growth is a major concern for the people who have lost their jobs and livelihood amid the pandemic. The overall situation has increased stress and panic. Staying at home is no more a luxury and mental health has become a major matter of concern. Hence, this is giving rise to various kinds of struggles and health problems. Insomnia is one of them which is increasing amongst the population with each passing day. 

Owing to the disorder of insomnia being highly prevalent, the government is investing in treatments and devices that will help in detecting insomnia. Also, the key market players are investing in the research and development areas that will enhance the availability of treatment, medicine, and drugs, for curing the patients suffering from insomnia. 

Figure 1- Global Insomnia Market Share, by region Insomnia Market

Market Dynamics


The work conditions are presently a lot of stress for the employees which are further resulting in tension, constant thinking, and loss of sleep. Also, the insomnia market is witnessing a huge demand for OTC drugs amongst the different age groups of patients that are suffering from insomnia. Also, owing to the rising incidence of insomnia amongst people due to numerous reasons like tension and stress is likely to act as major drivers for the global growth of the insomnia market by the end of the forecast period in 2021. 


The wide-scale availability of the pharmacological alongside the non-pharmacological treatment is the key market opportunity that will help the insomnia market growth for the forecast period ending in 2021. 

Technology Analysis

Difficulty in sleeping or having a sound sleep is what is understood as the problem of insomnia. There are a variety of symptoms that include insomnia like having low stamina, feeling sleepy during the daytime, depression, and having a constant feeling of irritation. There can be many conditions that lead to insomnia and sometimes, excessive use of drugs can result in the same. However, healthcare services like attempts for the timely development of detection devices are going to help value towards patients that will further help the insomnia market grow as per the expected CAGR rate. These devices are further helpful in detecting the insomnia stage in sleep laboratories. 

Study Objectives

  • To have a detailed review and understanding of the market functions and further noticing the market dynamics like the drivers and growth opportunities along with the challenges that the market is exposed to

  • To have the market insights like market segmentation and know the steps that will have a positive impact on the insomnia market growth as per the prediction for the forecast period ending in 2021

  • To help the insomnia market with a competitive egress based on the steps undertaken like the recent developments by the key market players in various regions across the globe 

Segment Overview

Based on the demand for the treatment for insomnia, the insomnia market has been segmented to cater to the demands of people having different stages and symptoms of insomnia. The market segments are as follows: 

By therapy

Based on the therapy for patients suffering from insomnia, both pharmacological and non-pharmacological therapy is available. Pharmacological therapy is further divided into prescription sleep aids, alongside, over-the-counter sleep aids. Further, non-pharmacological therapy includes hypnotherapy, medical devices, and cognitive behavioral therapy.

By region

Based on the regions, the insomnia market is providing its services in global regions like North America, the Middle East, and Africa, alongside Asian Pacific countries and Europe.

By drug formulation

Medicinal drugs for patients suffering from insomnia are available in the form of capsules and tablets amongst others. These can be taken on the prescription as recommended by the doctor.

Disease condition

The patients suffering from insomnia have disease conditions like poor sleep quality, maintenance of sleep, and having qualitative sleep amongst others. 

Regional Analysis

As mentioned, the global insomnia industry is functional in four major geographies of the world. The North American region is expected to have the highest growth in the global insomnia market. The reason behind this splendid growth resulting in domination for the insomnia market is the timely introduction of new technologies for the potential customers in the market. A similar trend has been adopted by the European countries which are promising a good return for their efforts in the future. However, the APAC region, along with the Middle East and African regions have the lowest market for Insomnia patients and a lot of investment and efforts are required for the insomnia market growth here by the end of the forecast period in 2021.                                                         

Competitive Landscape

The report discusses the scope of the global insomnia market by analyzing the recent developments of the key market players in several locations across the globe. Also, to draw the competitive market landscape, it is important to know the key market players. These are as follows:

  • Vanda Pharmaceuticals Inc. (US)

  • Neurim (Switzerland)

  • Eisai, Co. (Japan)

  • Purdue Pharma L.P. (US)

  • Merck & Co Inc (US)

  • Pfizer, Inc. (US)

  • Astellas (UK)

  • Flynn Pharma (UK)

  • Takeda Pharmaceutical Company (Japan)

  • SkyePharma (UK)

  • Meda Consumer Healthcare Inc (US)

  • Sanofi (France)

  • Biocodex S A (France)

  • Pernix Therapeutics (US)

  • Consumer Healthcare Inc. (Canada)

  • Purdue Pharma L.P. (US)

  • Dainippon Sumitomo (Japan)

  • ECR Pharmaceuticals (US)

  • Johnson & Johnson (US) 

Recent Developments

  • The key market players belonging to the North American region are taking major steps to maintain the demand for the psychotropic, alongside the analgesic drugs for medical purposes and treating patients suffering from insomnia-related issues. The efforts are constant and result-oriented that are likely to help the insomnia market reach the predicted CAGR growth by the end of the forecast period in 2021.

  • The insomnia market players are also focusing on bridging the gap between the industrialized and non-industrialized countries so that the risks related to over and underutilization of the required drugs are dissolved and do not harm the patients’ health.

  • The developed countries are putting efforts into the development of drugs that act as potential and significant solutions to treat patients with insomnia and sleeping disorders. Clinical trials are on the way to launch new and promising agents in the global insomnia market for mass benefit.

  • The European Sleep Research Society has laid down guidelines for the diagnosis alongside the treatment of patients suffering from insomnia. The guidelines laid further talk about the use of light therapy and exercise that are seen as potential and useful getaways to treat insomnia. However, the evidence for the same is weak and low as of now. 

Report Overview

The insomnia market trends are prevalent in various parts of the globe owing to people developing this illness as a result of major factors like tension, stress, lifestyle changes, overthinking, and depression amongst others. The report discusses the scope of the insomnia market during the forecast period that ends in 2021. The report discusses the drivers and opportunities available to the market and the impact of the global coronavirus pandemic on the market functions. The report also discusses the insomnia market segments and mentions the performance of these segments in various mushrooming regions around the globe. The market report also aims to analyze the prevalent degree of competition in the current forecast period that ends in 2021 to predict the future CAGR and market valuation figures. The report considers the performance of the key market players by considering their recent developments before predicting the final figures with the help of industry experts and leaders.


Report Scope:

Report Attribute/Metric Details
  Market Size   USD 6.6 Billion
  CAGR   3.11%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Types of Therapy, Drug formulation, Type of Diseases
  Geographies Covered   North America, Europe, Asia-Pacific and Rest of the World (RoW)
  Key Vendors   Eisai, Co. (Japan), Pfizer, Inc. (US), Merck & Co Inc (US), Sanofi (France), Takeda Pharmaceutical Company (Japan), Meda Consumer Healthcare Inc (US), Pernix Therapeutics (US), Purdue Pharma L.P. (US), Consumer Healthcare Inc. (Canada), Dainippon Sumitomo (Japan), ECR Pharmaceuticals (US), Flynn Pharma (UK), Johnson & Johnson (US), Astellas (UK), Biocodex S A (France), Neurim (Switzerland), SkyePharma (UK), and Vanda Pharmaceuticals Inc. (US)
  Key Market Opportunities   Pharmacological and non-pharmacological treatment
  Key Market Drivers

  • Increasing stressful work condition
  • Growing demand for OTC drugs
  • Rising incidence of insomnia

  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Insomnia is a common sleep disorder characterized by difficulties in sleep. Insomnia can exist as it’s alone or conjugated with other psychiatric problems. Insomnia is most common is women and the severity may increase in conditions like pregnancy, postpartum, and menopause.

    The exact cause of insomnia is still a mystery. Many research has shown that biological, behavioural and psychological factors are responsible for initiating of insomnia. Different types of treatment are available in the market- Pharmacological and non-pharmacological treatment.

    The insomnia market is predicted to grow at an 3.11% CAGR between 2022-2030.

    North America is predicted to have the highest share in the insomnia market.

    Increasing stressful work condition, growing demand for OTC drugs, and rising incidence of insomnia are boosting market growth.

    Presence of fake drugs coupled with strict reimbursement policies may deter market growth.

    Key players have incorporated different strategies players to maintain their dominance in the insomnia market such as joint ventures, partnerships, mergers, collaborations, and others.

    The availability of both pharmacological and non-pharmacological treatment is the biggest growth opportunity